Real-world experience in treatment of donor-derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care.
direct‐acting antiviral agents
hepatitis C
infectious
kidney disease
kidney transplantation
sustained virologic response
viral
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
revised:
30
07
2024
received:
15
12
2023
accepted:
09
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
There is limited literature describing the real-world practice of delayed initiation and shortened duration direct-acting antiviral (DAA) in kidney transplant recipients. We compared Hepatitis C virus (HCV) cure rates among kidney transplant recipients who received an HCV nucleic acid test positive (NAT +) kidney and were treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks or glecaprevir/pibrentasvir (G/P) for 8 weeks, a duration that is 4 weeks shorter than the guideline recommendation for treatment delay beyond 1-week post-transplant. Retrospective study of HCV-negative adult patients who received a kidney transplant from an HCV NAT+ donor between April 2019 and April 2022 treated with either SOF/VEL for 12 weeks or G/P for 8 weeks. The primary outcome was sustained virologic response 12 weeks after completion of therapy (SVR12). Secondary outcomes included time to DAA initiation, renal function, graft loss, patient death, liver function tests, and opportunistic infections. 102 kidney transplant recipients were included with 36 treated with G/P and 66 treated with SOF/VEL. All 36 (100%) treated with G/P achieved SVR12. One patient in the SOF/VEL group failed to achieve SVR12 but received additional therapy and was cured. Time to DAA initiation was similar with a mean of 4 weeks. There was no difference in AST/ALT > 3x ULN or renal function. One rejection occurred in each group. No patient death or graft loss was observed. There was no difference in cytomegalovirus and BK viremia between groups. CONCLUSION: Delayed initiation of DAA therapy with 12 weeks of SOF/VEL or 8 weeks of G/P achieves SVR12 in kidney transplant recipients without significant adverse effects.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited literature describing the real-world practice of delayed initiation and shortened duration direct-acting antiviral (DAA) in kidney transplant recipients. We compared Hepatitis C virus (HCV) cure rates among kidney transplant recipients who received an HCV nucleic acid test positive (NAT +) kidney and were treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks or glecaprevir/pibrentasvir (G/P) for 8 weeks, a duration that is 4 weeks shorter than the guideline recommendation for treatment delay beyond 1-week post-transplant.
METHODS
METHODS
Retrospective study of HCV-negative adult patients who received a kidney transplant from an HCV NAT+ donor between April 2019 and April 2022 treated with either SOF/VEL for 12 weeks or G/P for 8 weeks. The primary outcome was sustained virologic response 12 weeks after completion of therapy (SVR12). Secondary outcomes included time to DAA initiation, renal function, graft loss, patient death, liver function tests, and opportunistic infections.
RESULTS
RESULTS
102 kidney transplant recipients were included with 36 treated with G/P and 66 treated with SOF/VEL. All 36 (100%) treated with G/P achieved SVR12. One patient in the SOF/VEL group failed to achieve SVR12 but received additional therapy and was cured. Time to DAA initiation was similar with a mean of 4 weeks. There was no difference in AST/ALT > 3x ULN or renal function. One rejection occurred in each group. No patient death or graft loss was observed. There was no difference in cytomegalovirus and BK viremia between groups. CONCLUSION: Delayed initiation of DAA therapy with 12 weeks of SOF/VEL or 8 weeks of G/P achieves SVR12 in kidney transplant recipients without significant adverse effects.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14366Informations de copyright
© 2024 The Author(s). Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts. Transplant Rev. 2022;36(1):100677. doi:10.1016/j.trre.2021.100677
Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for Hepatitis C screening among adults – United States, 2020. MMWR Recomm Rep. 2020;69(2):1‐17. doi:10.15585/MMWR.RR6902A1
Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of Hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790‐2802. doi:10.1111/ajt.14381
Xu Y, Zhang Y, Wang J. Hepatitis C guidance 2019 update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Chin J Clin Infect Dis. 2020;13(2):686‐721.. doi:10.3760/cma.j.issn.1674‐2397.2020.02.001
Durand CM, Bowring MG, Brown DM, et al. Direct‐acting antiviral prophylaxis in kidney transplantation from hepatitis C virus‐infected donors to noninfected recipients an open‐label nonrandomized trial. Ann Intern Med. 2018;168(8):533‐540. doi:10.7326/M17‐2871
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV‐infected kidneys into uninfected recipients. New Engl J Med. 2017;376(24):2394‐2395. doi:10.1056/nejmc1705221
Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C‐infected kidneys (mythic): An open‐label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678‐2687. doi:10.1681/ASN.2020050686
Feld JJ, Cypel M, Kumar D, et al. Short‐course, direct‐acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV‐infected donors: a phase 3, single‐centre, open‐label study. Lancet Gastroenterol Hepatol. 2020;5(7):649‐657. doi:10.1016/S2468‐1253(20)30081‐9
Terrault NA, Burton J, Ghobrial M, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV‐viremic donors. Hepatology. 2021;73(6):2110‐2123. doi:10.1002/hep.31551
Kosloski MP, Zhao W, Li H, et al. Drug‐drug interactions of tacrolimus or cyclosporine with glecaprevir and pibrentasvir in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(6):779‐789. doi:10.1002/cpdd.671
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377‐381. doi:10.1016/j.jbi.2008.08.010
Chan A, Patel K, Naggie S. Genotype 3 infection: the last stand of hepatitis C virus. Drugs. 2017;77(2):131‐144. doi:10.1007/s40265‐016‐0685‐x
Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: single center experience. Am J Transplant. 2019;19(11):3046‐3057. doi:10.1111/ajt.15530
Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C‐positive donor to negative recipient kidney transplantation: a real‐world experience. Transpl Infect Dis. 2021;23(3):e13540. doi:10.1111/tid.13540
Kapila N, Menon KVN, Al‐Khalloufi K, et al. Hepatitis C virus NAT‐positive solid organ allografts transplanted into hepatitis C virus‐negative recipients: a real‐world experience. Hepatology. 2020;72(1):32‐41. doi:10.1002/hep.31011
Aleyadeh W, Verna E, Elbeshbeshy H, et al. Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV‐uninfected recipients: results from the HCV‐TARGET study. J Hepatol. 2024;78:468‐478. doi:10.1016/s0168‐8278(23)00578‐0
Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1‐year outcomes with transplantation of HCV‐viremic kidneys. J Am Soc Nephrol. 2019;30(10):1939‐1951. doi:10.1681/ASN.2019050462
Bodro M, Londoño MC, Esforzado N, et al. Hepatitis C viremia as a risk factor for opportunistic infections in kidney transplant recipients. Clin Transplant. 2018;32(10):e13382. doi:10.1111/ctr.13382
Nnani DU, Campbell A, Ajaimy M, et al. Effect of glecaprevir/pibrentasvir on weight‐adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. Transpl Infect Dis. 2021;23(5):e13716. doi:10.1111/tid.13716